Seven patients were also tested for reactivity against FOXL2 peptides, and we demonstrated that 4 of them (57.1%) possessed FOXL2-specific TILs, suggesting that FOXL2 is an ideal target in GCT. This evidence concerns the gene FOXL2 and granular cell tumor.